Genmab — November 2022
-
Although it fell short of response rates shown by its Car-T cell competitors the US approval of J&J ,s Tecvayli on tuesday along with some winning attributes has set it up as a major player in the multiple myeloma treatment paradigm according to key opinion leaders in the field
-
https://ir.horizontherapeutics.com/static-files/b3e39f27-2ed6-4c37-843a-d17b24e1b8b8 Horizon Q3 2022 Presentation
-
Jeg øgede kraftigt min eksponering i $HZNP efter tilbagefaldet ovenpå Q2. Godt at se de allerede har fået hånd om situationen. Ikke overraskende at de går ind i Europa. Det har undret mig længe, at de ikke var mere sultne på det globale potentiale for TEPEZZA.
-
From the viewpoint also: Besides, experts said they foresee the way being paved for Tecvayli to move into earlier lines of treatment relatively quickly. Analysts from Morgan Stanley pointed out that J&J has trials underway to do just that, and said this helps to bolster the sunny revenue outlook for the company’s multiple myeloma assets, projecting sales of Tecvayli to reach $6.6 billion by 2030 and Carvykti sales to garner $5.7 billion in that same time frame.
-
-
4 oral presentations of epco. 19 in total from Genmab
-
3254 Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody
-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) https://ash.confex.com/ash/2022/webprogram/Paper159116.html -
and from Mathai Mammen, when he was still at JNJ, -This study with the HexaBody is being run by Genmab in close collaboration with us. And it's a next generation even more effective CD38 blocker, deep activity on CD38 positive cells. And we'll see data towards the end of this year that'll help us understand whether there's a path forward, both in multiple myeloma, by the way, and diffuse large cell B cell lymphoma. And so, this is exciting for us.
-
ASH 1366 Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30+ Hematologic Malignancies https://ash.confex.com/ash/2022/webprogram/Paper159396.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind